Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank86
3Y CAGR-6.6%
5Y CAGR+1.3%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
-6.6%/yr
vs +35.2%/yr prior
5Y CAGR
+1.3%/yr
Recent deceleration
Acceleration
-41.8pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $3.19B | +504.1% |
| 2024 | $-790.30M | -124.1% |
| 2023 | $3.28B | -16.5% |
| 2022 | $3.93B | +63.0% |
| 2021 | $2.41B | -19.5% |
| 2020 | $2.99B | +100.4% |
| 2019 | $1.49B | +27.2% |
| 2018 | $1.17B | +100.6% |
| 2017 | $585.52M | +226.1% |
| 2016 | $179.54M | - |